title: Liposome armed with herpes virus-derived gH625 peptide to overcome doxorubicin resistance in lung adenocarcinoma cell lines.
abstract: New delivery systems including liposomes have been developed to circumvent drug resistance. To enhance the antitumor efficacy of liposomes encapsulating anti-cancer agents, we used liposomes externally conjugated to the 20 residue peptide gH625. Physicochemical characterization of the liposome system showed a size of 140 nm with uniform distribution and high doxorubicin encapsulation efficiency. We evaluated the effects of increasing concentrations of liposomes encapsulating Doxo (LipoDoxo), liposomes encapsulating Doxo conjugated to gH625 (LipoDoxo-gH625), empty liposomes (Lipo) or free Doxo on growth inhibition of either wild type (A549) or doxorubicin-resistant (A549 Dx) human lung adenocarcinoma. After 72 h, we found that the growth inhibition induced by LipoDoxo-gH625 was higher than that caused by LipoDoxo with an IC50 of 1 and 0.3 μM in A549 and A549 Dx cells, respectively. The data on cell growth inhibition were paralleled by an higher oxidative stress and an increased uptake of Doxo induced by LipoDoxo-gH625 compared to LipoDoxo, above all in A549 Dx cells. Cytometric analysis showed that the antiproliferative effects of each drug treatment were mainly due to the induction of apoptosis. In conclusion, liposomes armed with gH625 are able to overcome doxorubicin resistance in lung adenocarcinoma cell lines.
authors.affiliation: Department of Pharmacy and DFM Scarl - University of Naples "Federico II", Naples, Italy.
authors.forename: Emiliana
authors.initials: E
authors.lastname: Perillo
authors.affiliation: Department of Biochemistry, Biophysics and General Pathology, Second University of Naples, Naples, Italy.
authors.forename: Stefania
authors.initials: S
authors.lastname: Porto
authors.affiliation: Department of Pharmacy and DFM Scarl - University of Naples "Federico II", Naples, Italy.
authors.forename: Annarita
authors.initials: A
authors.lastname: Falanga
authors.affiliation: Department of Biochemistry, Biophysics and General Pathology, Second University of Naples, Naples, Italy.
authors.forename: Silvia
authors.initials: S
authors.lastname: Zappavigna
authors.affiliation: Department of Biochemistry, Biophysics and General Pathology, Second University of Naples, Naples, Italy.
authors.forename: Paola
authors.initials: P
authors.lastname: Stiuso
authors.affiliation: Department of Experimental Medicine, Section of Biotechnology and Medical Histology and Embryology, Second University of Naples, Naples, Italy.
authors.forename: Virginia
authors.initials: V
authors.lastname: Tirino
authors.affiliation: Department of Experimental Medicine, Section of Biotechnology and Medical Histology and Embryology, Second University of Naples, Naples, Italy.
authors.forename: Vincenzo
authors.initials: V
authors.lastname: Desiderio
authors.affiliation: Department of Experimental Medicine, Section of Biotechnology and Medical Histology and Embryology, Second University of Naples, Naples, Italy.
authors.forename: Gianpaolo
authors.initials: G
authors.lastname: Papaccio
authors.affiliation: Department of Experimental Medicine - Second University of Naples, Naples, Italy.
authors.forename: Massimiliano
authors.initials: M
authors.lastname: Galdiero
authors.affiliation: Sbarro Institute for Cancer Research and Molecular Medicine, Center for Biotechnology, College of Science and Technology, Temple University, Philadelphia, PA, USA.|Department of Medicine, Surgery and Neuroscience, University of Siena, Siena, Italy.
authors.forename: Antonio
authors.initials: A
authors.lastname: Giordano
authors.affiliation: Department of Pharmacy and DFM Scarl - University of Naples "Federico II", Naples, Italy.
authors.forename: Stefania
authors.initials: S
authors.lastname: Galdiero
authors.affiliation: Department of Biochemistry, Biophysics and General Pathology, Second University of Naples, Naples, Italy.|Sbarro Institute for Cancer Research and Molecular Medicine, Center for Biotechnology, College of Science and Technology, Temple University, Philadelphia, PA, USA.|Department of Medicine, Surgery and Neuroscience, University of Siena, Siena, Italy.
authors.forename: Michele
authors.initials: M
authors.lastname: Caraglia
mesh_terms: D000230:Adenocarcinoma / Q000188:drug therapy / Q000378:metabolism / Q000473:pathology; D000903:Antibiotics, Antineoplastic / Q000008:administration & dosage* / Q000737:chemistry; D017209:Apoptosis / Q000187:drug effects; D015153:Blotting, Western; D002289:Carcinoma, Non-Small-Cell Lung / Q000188:drug therapy / Q000378:metabolism / Q000473:pathology; D049109:Cell Proliferation / Q000187:drug effects; D004317:Doxorubicin / Q000008:administration & dosage* / Q000737:chemistry; D019008:Drug Resistance, Neoplasm / Q000187:drug effects*; D005434:Flow Cytometry; D006801:Humans; D008081:Liposomes / Q000008:administration & dosage / Q000737:chemistry*; D008175:Lung Neoplasms / Q000188:drug therapy* / Q000378:metabolism / Q000473:pathology; D018613:Microscopy, Confocal; D018384:Oxidative Stress / Q000187:drug effects; D010455:Peptides / Q000008:administration & dosage* / Q000737:chemistry; D014407:Tumor Cells, Cultured; D014759:Viral Envelope Proteins / Q000008:administration & dosage* / Q000737:chemistry
chemical_list: D000903:Antibiotics, Antineoplastic; D008081:Liposomes; D010455:Peptides; D014759:Viral Envelope Proteins; C569201:gH625 peptide, Herpes simplex virus type I; D004317:Doxorubicin
keywords: doxorubicin; drug resistance; liposome; lung adenocarcinoma; membranotropic peptide